曲妥珠单抗联合改良DCF方案治疗HER2阳性晚期胃癌患者的护理

目的 总结人表皮生长因子受体2（HER2）阳性晚期胃癌患者应用曲妥珠单抗联合改良DCF方案化疗的护理体会.方法 回顾性分析2011年1月至2012年12月收治的20例应用曲妥珠单抗联合改良DCF方案治疗HER2阳性晚期胃癌患者的临床资料,并总结护理要点.结果 20例患者经过联合治疗后疾病控制率为80％,主要不良反应为骨髓抑制12例、恶心或呕吐7例、心脏毒性5例、高血糖3例、低钠血症3例、肝功能损害3例、口腔炎2例,程度Ⅰ～Ⅲ级,经对症治疗与护理后,不良反应均得到缓解,取得了满意的疗效.结论 HER2阳性晚期胃癌患者应用曲妥珠单抗联合改良DCF方案化疗是一种新的、有效的治疗方法,采用针对性的护理措施可以减少和改善患者治疗期间的不良反应,提高生活质量.

Nursing of the patients with HER2-positive advanced gastric cancer who were treated with trastuzumab combination with modified DCF regimen chemotherapy

Objective To summarize experience of nursing the patients with human epidermal growth factor receptor 2 （HER-2）-positive advanced gastric cancer who were treated with trastuzumab combination with modified DCF regimen chemotherapy.Methods We retrospectively analyzed the clinical materials from 20 patients with HER2-positive advanced gastric cancer who were treated with trastuzumab combination with modified DCF regimen chemotherapy during January 2011 and December 2012,and summarized the key point of nursing.Results The rate of disease control was 80％ in 20 patients after the combined treatment.The main adverse events were 12 cases of neutropenia,7 cases of nausea/vomiting,5 cases of cardiac toxicity,3 cases of hyperglycemia,3 cases of hyponatremia,3cases of liver function damage and 2 cases of stomatitis,and the degree of adverse reactions was grade Ⅰ-Ⅲ.The main adverse events were relieved after the corresponding treatment and nursing,and have obtained the satisfactory curative effect.Conclusions Application of trastuzumab combination with modified DCF regimen in patients with HER2-positive advanced gastric cancer was novel,effective treatment method.Taking corresponding nursing measures can ameliorate and reduce adverse reactions and improve the life quality of patients during the treatment.